Thyroid-Stimulating Hormone Levels in Non-Alcoholic Fatty Liver Disease: Implications for Type 2 Diabetes Risk and Adiponectin Association in Euthyroid Subjects

Abstract

Background: The regulation of body weight, lipid metabolism, and insulin resistance is entirely dependent on thyroid hormones. Thyroid hormones are therefore thought to be involved in the pathophysiology of non-alcoholic fatty liver disease (NAFLD). Aim: the aim of this study was biochemical evaluation of serum thyroid stimulating hormone (TSH) and serum Adiponectin levels in non-alcoholic fatty liver disease (NAFLD), euthyroid subjects as a risk for T2DM.Patient and methods: a prospective study was held in Internal medicine department and clinical pathology department. The study lasted from March 2023 to December 2023, 82 subjects were collected from outpatient clinic, divided into three groups, first group 24 fatty liver only patients, second group24 fatty liver and type 2 diabetic patients, 34third control group.Serum TSH, also Adiponectin were assessed in the three groups.Results: TSH levels exhibited significant differences among the groups (p < 0.001). Post-hoc analysis indicated a significant increase in TSH levels in NAFLD and type 2 diabetic group compared to NAFLD only group I (p value < 0.001) and control group (p value< 0.001).Serum Adiponectin level was significantly lower in type2 diabetic and NAFLD patients in comparison with NAFLD only group with (P value <0.003).Conclusion: Prominent increase in thyroid-stimulating hormone concentration and decreased adiponectin level can be additional risk factors for the development of type 2 diabetes in fatty liver euthyroid subjects.Keywords: NAFLD, type 2diabetes, (TSH) Thyroid stimulating hormone.